PA
ASBP

Procyon Advisors’s Aspire Biopharma ASBP Stock Holding History

Procyon Advisors’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-194
Closed -$30.7K – 627
2025
Q4 		$30.7K Sell
194
-200
-51% -$50K ﹤0.01% 556
2025
Q3 		$97.4K Sell
394
-146
-27% -$73.1K 0.01% 502
2025
Q2 		$174K Buy
540
+458
+559% +$217K 0.02% 457
2025
Q1 		$57.4K Buy
+82
New +$567K ﹤0.01% 590

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Procyon Advisors's ASBP Position: Q1 2026 in Review

Procyon Advisors sold out of Aspire Biopharma (ASBP) in Q1 2026, closing a stake of 194 shares — an estimated $30.7K sold.

Procyon Advisors first reported a position in ASBP in Q1 2025 and held it in 4 quarters. The position peaked at $174K in Q2 2025. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • Procyon Advisors reported no remaining Aspire Biopharma position as of Q1 2026 after selling out during the quarter.
  • Procyon Advisors sold 194 Aspire Biopharma shares in Q1 2026, an estimated $30.7K.
  • Procyon Advisors first reported a position in Aspire Biopharma in Q1 2025 and held it in 4 quarters.
  • Procyon Advisors's Aspire Biopharma position peaked at $174K in Q2 2025.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Procyon Advisors's 13F filing for Q1 2026, filed 4 May 2026.